N@N

Market Maker Surveillance Report. CRTN, NOVN, ESSI, BIOA, OCUL, APTO, Losing Stocks With Lowest Price Friction For Monday, Jan

^{Published on 2017-01-23 18:45:31 - WOPRAI}
 

January 23, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 5592 companies with "abnormal" market making, 3094 companies with positive Friction Factors and 3008 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Monday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Cartesian Inc. (NASDAQ:CRTN), Novan (NASDAQ:NOVN), ECO SCIENCE SOLUTION (OTC:ESSI), BioAmber Inc. (NYSE:BIOA), Ocular Therapeutix (NASDAQ:OCUL), Aptose Biosciences Inc. (NASDAQ:APTO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  CRTN    $-0.170   -0.12%    255,144      32.86%    334,731      43.12%    -79,587      -4,682  
  NOVN    $-2.630   -0.12%    71,571       28.64%    84,378       33.77%    -12,807      -49     
  ESSI    $-0.590   -0.13%    648,834      41.73%    834,637      53.68%    -185,803     -3,149  
  BIOA    $-0.660   -0.11%    55,712       31.93%    67,344       38.59%    -11,632      -176    
  OCUL    $-0.990   -0.13%    267,533      35.92%    302,357      40.59%    -34,824      -352    
  APTO    $-0.240   -0.18%    664,366      29.75%    805,186      36.06%    -140,820     -5,868  

For example, the chart above shows CRTN with a dollar loss Monday of $-0.17000 and a Friction Factor of -4,682 shares. That means that it only took 4,682 more shares of selling than buying to move CRTN lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

Cartesian Inc. (NASDAQ:CRTN) - CERTRON CORP.

Novan (NASDAQ:NOVN) - Noven Pharmaceuticals, Inc. (Noven), incorporated in 1987, is engaged in the development and commercialization of advanced transdermal drug delivery products and technologies and prescription transdermal products. The Company's principal commercialized products are prescription transdermal patches for use in menopausal hormone therapy (HT). Vivelle-Dot (estradiol transdermal system) is a transdermal estrogen therapy product marketed primarily under the brand name Estradot outside the United States. Vivelle (estradiol transdermal system) is an estrogen patch marketed under the brand name Femiest in Japan and Menorest in countries outside the United States and Canada. CombiPatch (estradiol/norethindrone acetate transdermal system) is the first combination estrogen/progestin transdermal patch marketed under the brand name Estalis outside the United States. Its first transmucosal delivery system is DentiPatch.

Hormone Therapy Products

Noven's HT products are indicated for menopausal symptoms. The Company's menopausal hormone therapy products are marketed and sold in the United States through Novogyne Pharmaceuticals (Novogyne), a joint venture that the Company formed with Novartis Pharmaceuticals Corporation (Novartis) in 1998 to market and sell women's prescription healthcare products. Noven owns a 49% equity interest in the joint venture company and Novartis owns the remaining 51% equity interest. Novogyne markets Vivelle-Dot, Vivelle, and CombiPatch products in the United States. Noven derives a significant portion of its revenues from its HT products, which represented 83%, 87% and 96% of the Company's revenues in years ended 2005, 2004 and 2003, respectively.

Noven is working with Procter and Gamble Pharmaceuticals, Inc. (P and G Pharmaceuticals) to develop prescription transdermal patches for Hypoactive Sexual Desire Disorder (HSDD). The products under development explore follow-on product opportunities for Intrinsa, P and G Pharmaceuticals' in-licensed investigational transdermal testosterone patch designed to help restore sexual desire in menopausal women diagnosed with HSDD. P and G Pharmaceuticals withdrew its New Drug Application (NDA) for Intrinsa in December 2004 based on feedback from an Food and Drug Administration (FDA) Advisory Committee and has indicated that it is working to identify a clinical strategy intended to address the FDA's safety concerns related to this product.

In July 2003, Noven submitted an Abbreviated New Drug Application (ANDA) to the FDA seeking approval to market a generic fentanyl patch. The Company entered into an agreement with Endo Pharmaceuticals Inc. (Endo) in the first quarter of 2004 granting Endo the exclusive right to market the Company's fentanyl patch in the United States. In July 2005, the FDA issued a public advisory that it is investigating reports of death and other serious side effects from overdoses involving both the branded and generic fentanyl patches. In September 2005, the FDA advised Noven that it did not expect to approve the Company's ANDA and was consequently ceasing its review of its ANDA, based on the FDA's assessment of potential safety concerns related to the higher drug content in Noven's generic product versus the branded product. Due to the FDA's determination, Noven and Endo agreed in December 2005 to terminate the fentanyl portion of the 2004 license agreement, as well as the fentanyl supply agreement. Noven is evaluating the feasibility of reformulating the fentanyl patch to address the FDA's concerns, and has granted Endo a right of first negotiation with respect to any reformulated fentanyl patch that it may develop. Noven and Endo continue to proceed with other areas of their development collaboration that are unrelated to fentanyl.

The Company has an NDA pending with the FDA for a once-daily methylphenidate patch for the treatment of ADHD with the proposed brand name Daytrana (methylphenidate transdermal system). Noven has licensed the exclusive global rights to market its methylphenidate patch to Shire plc (Shire). In December 200.

ECO SCIENCE SOLUTION (OTC:ESSI) - Eco Science Solutions, Inc., a technology-focused company, provides solutions for the health and wellness industry. It develops and offers enterprise software solutions; entertaining and content generation solutions for mass distribution; consumer applications for daily use; and technical solutions that allow enthusiasts in building eco-friendly businesses and living healthy lifestyles. The company s services include business location, localized communications between consumers and business operators, social networking, educational content, e-commerce, and delivery. Its e-commerce platform enables health-and-wellness enthusiasts to locate, access, and connect with health-and-wellness businesses and like-minded enthusiasts, as well as facilitates research and purchasing of eco-friendly products. In addition, the company offers Herbo app that enables consumers to find products and services, which support the intake of alternative medicines for a naturopathic way of living; and Fitrix app that helps to track day-to-day fitness routines, dietary habits, and alternative medicine intake. Eco Science Solutions, Inc. was founded in 2009 and is headquartered in Makawao, Hawaii..

BioAmber Inc. (NYSE:BIOA) - .

Ocular Therapeutix (NASDAQ:OCUL) - .

Aptose Biosciences Inc. (NASDAQ:APTO) - .

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net